Last reviewed · How we verify

Sore throat symptom — Treatment Landscape & Competitive Intelligence

Sore throat symptom (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Sore throat symptom, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Delsym dextromethorphan Generic (originally Roche) Antitussive (non-opioid) Taste receptor type 2 member 46, Solute carrier family 22 member 1, Cytochrome P450 2D6 1958-01-01
Codeine codeine phosphate Generic (multiple manufacturers) Opioid analgesic, Antitussive Delta-type opioid receptor, Kappa-type opioid receptor, Mu-type opioid receptor 1950-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 2 drugs in Sore throat symptom
  2. Generic (multiple manufacturers) · 1 drug in Sore throat symptom
  3. Generic (originally Roche) · 1 drug in Sore throat symptom

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Sore throat symptom:

Cite this brief

Drug Landscape (2026). Sore throat symptom — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/sore-throat-symptom. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing